🔎 Trials Near Me

Beranda › Neuroblastoma › Alabama

Uji klinis Neuroblastoma di Alabama

8 studi untuk Neuroblastoma mencari peserta di lokasi di Alabama.

Kota di Alabama

Teks studi resmi (Bahasa Inggris)

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

  • Children's Hospital of Alabama, Birmingham
  • USA Health Strada Patient Care Center, Mobile
Menerima pesertaFase 3
Hingga usia 30 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06172296

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

  • University of Alabama/Children's of Alabama, Birmingham
Menerima pesertaFase 2
Hingga usia 22 · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT02559778

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

  • University of Alabama/Children's of Alabama, Birmingham
Menerima pesertaFase 1/2
Hingga usia 26 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06465199

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

  • University of Alabama/Children's of Alabama, Birmingham
Menerima pesertaFase 1/2
Hingga usia 30 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06541262

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

  • Children's Hospital of Alabama, Birmingham
Menerima pesertaFase 3
365 Days – 30 Years · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT03126916

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Children's Hospital of Alabama, Birmingham
Menerima pesertaFase 1/2
12 Months – 30 Years · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04851119

Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

  • University of Alabama/Children's of Alabama, Birmingham
Menerima pesertaFase 2
12 Months – 21 Years · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT05489887

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

  • Children's Hospital of Alabama/UAB, Birmingham
Menerima pesertaFase 2
18 Months – 40 Years · Semua jenis kelamin · Diperbarui 12 Agu 2025 · NCT05135975

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.